A Multi-institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors

A Multi-institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
In a multi-institute cohort study of patients treated with immune checkpoint inhibitors (ICIs) for advanced or metastatic cancers, we aim to identify patient and clinical predictors of exceptional response to ICI treatment and determine the longitudinal trajectory and influences of common long-term physiological and psychosocial effects from ICI treatment and of health-related quality of life and survival.
Funder: National Cancer Institute

0